Get the Stockscreener App
3.17
0.63%
-0.02
After Hours:
3.23
0.06
+1.89%
Nyxoah Sa stock is traded at $3.17, with a volume of 63,140.
It is down -0.63% in the last 24 hours and down -28.76% over the past month.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
See More
Previous Close:
$3.19
Open:
$3.18
24h Volume:
63,140
Relative Volume:
1.26
Market Cap:
$138.41M
Revenue:
$6.29M
Net Income/Loss:
$-92.76M
P/E Ratio:
-1.2765
EPS:
-2.4834
Net Cash Flow:
$-79.42M
1W Performance:
+3.59%
1M Performance:
-28.76%
6M Performance:
-29.40%
1Y Performance:
-72.02%
1-Day Range:
$3.13
$3.22
1-Week Range:
$3.02
$3.32
52-Week Range:
$3.02
$10.98
Nyxoah Sa Stock (NYXH) Company Profile
Name
Nyxoah Sa
Sector
Industry
Phone
-
Address
-
Compare NYXH vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NYXH
Nyxoah Sa
|
3.17 | 139.28M | 6.29M | -92.76M | -79.42M | -2.4834 |
ISRG
Intuitive Surgical Inc
|
469.98 | 167.61B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
158.27 | 44.35B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
75.26 | 36.19B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
42.67 | 34.11B | 28.43B | 1.16B | 1.26B | 1.4457 |
RMD
Resmed Inc
|
226.31 | 33.24B | 5.40B | 1.49B | 1.78B | 10.12 |
Nyxoah Sa Stock (NYXH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-23 | Initiated | H.C. Wainwright | Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Neutral |
| Apr-21-22 | Initiated | Oppenheimer | Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Dec-21-21 | Resumed | Cantor Fitzgerald | Overweight |
| Jul-28-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Nyxoah Sa Stock (NYXH) Latest News
Breakout Zone: Is Nyxoah SA a speculative investment2026 Rallies & Entry Point Strategy Guides - baoquankhu1.vn
Cantor Fitzgerald Reiterates Overweight Rating for NYXH, Price T - GuruFocus
Cantor Fitzgerald reiterates Nyxoah stock rating on U.S. launch - Investing.com UK
Nyxoah's (NYXH) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Stifel Maintains Nyxoah SA(NYXH.US) With Buy Rating, Cuts Target Price to $10 - 富途牛牛
New Highs: Will Nyxoah SA benefit from rising consumer demandQuarterly Risk Review & Reliable Intraday Trade Plans - baoquankhu1.vn
Nyxoah SA (NYXH) reports Q4 loss, misses revenue estimates - MSN
Nyxoah Details Early U.S. Genio Launch, Reimbursement Update at Oppenheimer MedTech Conference 2026 - MarketBeat
Nyxoah Discloses Taub Group’s 10.14% Stake After Threshold Crossing - TipRanks
Nyxoah (ENXTBR:NYXH) Losses Of €90 Million Keep Bearish Cash Runway Concerns In Focus - simplywall.st
Publication relating to transparency notifications - GlobeNewswire
Stifel Nicolaus Issues Pessimistic Forecast for Nyxoah (NASDAQ:NYXH) Stock Price - MarketBeat
Nyxoah (NYXH) Q4 2025 Earnings Call Transcript - AOL.com
NYXH Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Nyxoah SA (NYXH) Q4 2025 Earnings Call Highlights: U.S. Launch Success and Financial Challenges By GuruFocus - Investing.com Canada
Nyxoah (NASDAQ:NYXH) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS - MarketBeat
Nyxoah Q4 2025 Earnings Call Transcript - MarketBeat
Nyxoah SA reports results for the quarter ended December 31Earnings Summary - TradingView
NYXH: FDA approval and U.S. launch fueled 122% revenue growth and strong Q4 momentum - TradingView
Nyxoah Q4 Earnings Call Highlights - MarketBeat
Nyxoah SA (NYXH) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
NYXH: Transformative U.S. launch drove 122% revenue growth and strong Q4 momentum - TradingView
Nyxoah Leverages First Full U.S. Sales Quarter to Power Triple-Digit 2025 Revenue Growth - TipRanks
Nyxoah (NASDAQ: NYXH) doubles 2025 revenue as U.S. launch drives growth but losses deepen - Stock Titan
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results - 富途牛牛
Nyxoah SA (NYXH) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations - Bitget
What is the long term forecast for Nyxoah SA stockWeekly Trade Summary & AI Driven Stock Movement Reports - baoquankhu1.vn
Earnings To Watch: Nyxoah SA (XBRU:NYXH) Reports Q4 2025 Result - GuruFocus
Nyxoah SA expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Earnings Preview: Nyxoah SA to Report Financial Results on March 19 - 富途牛牛
Publication relating to transparency notification - GlobeNewswire
Nyxoah price target lowered to EUR 5 from EUR 7 at Baird - MSN
Nyxoah (NYXH) Stock Analysis Report | Ratings, Financials & Performance - Benzinga Japan
Nyxoah to Participate in the Oppenheimer 36th Annual Healthcare MedTech & Services Conference - GlobeNewswire
Trading Recap: Will Nyxoah SA benefit from rising consumer demandShare Buyback & Target Return Focused Picks - baoquankhu1.vn
Will Nyxoah SA benefit from rising consumer demandJuly 2025 Gainers & AI Driven Stock Movement Reports - baoquankhu1.vn
Technical Analysis: Does Nyxoah SA have a competitive edgeJuly 2025 Final Week & Safe Capital Growth Trade Ideas - baoquankhu1.vn
Aug Ideas: Can Nyxoah SA sustain its profitabilityPortfolio Growth Summary & Low Drawdown Investment Strategies - baoquankhu1.vn
Nyxoah to Release Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026 - The Manila Times
Nyxoah SA (NASDAQ:NYXH) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Cantor Fitzgerald Upgrades Nyxoah (NASDAQ:NYXH) to "Strong-Buy" - MarketBeat
Nyxoah (NYXH) Expected to Announce Earnings on Thursday - MarketBeat
Nyxoah SA (NASDAQ:NYXH) Short Interest Down 17.8% in February - MarketBeat
Trading the Move, Not the Narrative: (NYXH) Edition - Stock Traders Daily
Nyxoah (NYXH) Stock Forecast & Price Target - Investing.com
Nyxoah SA (NYXH) Stock Analysis: Exploring a 149% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Information on the total number of voting rights and shares - GlobeNewswire
EV Market: Should value investors consider CNVSTrade Signal Summary & Stock Market Timing Techniques - baoquankhu1.vn
Macro Review: Can Nyxoah SA expand into new marketsJuly 2025 Update & High Accuracy Investment Signals - baoquankhu1.vn
How The Nyxoah (ENXTBR:NYXH) Story Is Shifting As Assumptions And Risks Are Reworked - Yahoo Finance
What’s Nyxoah SA’s historical returnQuarterly Growth Report & Technical Entry and Exit Tips - mfd.ru
Nyxoah Sa Stock (NYXH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.95%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):